Citation Impact
Citing Papers
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
2008
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
Accurate de novo design of heterochiral protein–protein interactions
2024 StandoutNobel
A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
2004
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
2003
Regional Radiochemotherapy Using In Situ Hydrogel
2005
Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC
2008
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
2018
Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
2007
Common challenges and problems in clinical trials of boron neutron capture therapy of brain tumors
2003
Present Status of Boron Neutron Capture Therapy
1992
A Triazacyclononane‐Based Bifunctional Phosphinate Ligand for the Preparation of Multimeric 68Ga Tracers for Positron Emission Tomography
2010
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Toxic Mechanisms of Five Heavy Metals: Mercury, Lead, Chromium, Cadmium, and Arsenic
2021 Standout
Well‐differentiated thyroid carcinoma: The role of post‐operative radioactive iodine administration
2012
The Virtual Family—development of surface-based anatomical models of two adults and two children for dosimetric simulations
2009 Standout
68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression
2008
How is 68Ga Labeling of Macrocyclic Chelators Influenced by Metal Ion Contaminants in 68Ge/68Ga Generator Eluates?
2012
Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of 68Ga-TRAP(RGD)3
2012
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐D Phe1,Tyr3‐octreotate) and 18F‐FDG
2008
Clinical applications of newer radionuclide therapies
2006
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
2007
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
2003
A Monoreactive Bifunctional Triazacyclononane Phosphinate Chelator with High Selectivity for Gallium‐68
2012
Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours
2004
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
2009 Standout
Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients
2006
αvβ3 Integrin‐targeting radionuclide therapy and imaging with monomeric RGD peptide
2008
[68Ga]NS3-RGD and [68Ga] Oxo-DO3A-RGD for imaging αvβ3 integrin expression: synthesis, evaluation, and comparison
2012
Processing of Generator-Produced 68Ga for Medical Application
2007
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Peptide therapeutics: current status and future directions
2014 Standout
TRAP, a Powerful and Versatile Framework for Gallium‐68 Radiopharmaceuticals
2011
Infrared-based module for the synthesis of 68Ga-labeled radiotracers
2007
Cisplatin: The first metal based anticancer drug
2019 Standout
Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors
2003
68Ga‐PET: a powerful generator‐based alternative to cyclotron‐based PET radiopharmaceuticals
2008
Gallium-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma
2007
Towards clinically translatable in vivo nanodiagnostics
2017
The Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology
2011
Trends in peptide drug discovery
2021
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer
2007
Cadmium Nephrotoxicity Is Associated with Altered MicroRNA Expression in the Rat Renal Cortex
2018
Hydrogels in Biology and Medicine: From Molecular Principles to Bionanotechnology
2006 Standout
Gallium(III) Complexes of DOTA and DOTA−Monoamide: Kinetic and Thermodynamic Studies
2010
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice Using64Cu- and86Y-DOTA−(Pro1,Tyr4)-Bombesin(1−14)
2007
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
2006
Production and Purification of Metal Radionuclides for PET Imaging of Disease
2013
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer
2010
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
2014
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
2004
Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era
2010
Agonist−Antagonist Dilemma in Molecular Imaging: Evaluation of a Monomolecular Multimodal Imaging Agent for the Somatostatin Receptor
2007
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
2005
Protein-Catalyzed Capture Agents
2019
Computational Anthropomorphic Models of the Human Anatomy: The Path to Realistic Monte Carlo Modeling in Radiological Sciences
2007
Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal
2009
Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome
2012
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules - 2016 Update Appendix
2016 Standout
The Chemistry of Neutron Capture Therapy
1998 Standout
Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications
2015
Mono- and Bis-Alkylation of Glyoxal-Bridged Tetraazamacrocycles Using Mechanochemistry
2015
Platinum(IV) Prodrugs – A Step Closer to Ehrlich's Vision?
2016
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
2005 Standout
Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
2009
Guidelines for the management of thyroid cancer
2014 Standout
Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review
2005
Radiometals for Combined Imaging and Therapy
2012
Mechanochemistry as an emerging tool for molecular synthesis: what can it offer?
2018 Standout
Cancer treatment and survivorship statistics, 2014
2014 Standout
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
2003
Works of Mark Konijnenberg being referenced
Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes.
2000
Is the Renal Dosimetry for [ 90 Y-DOTA 0 , Tyr 3 ]Octreotide Accurate Enough to Predict Thresholds for Individual Patients?
2003
Preclinical animal research on therapy dosimetry with dual isotopes
2011
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
2016
Utilizing High-Energy γ-Photons for High-Resolution 213Bi SPECT in Mice
2015
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
2001
68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives
2011
Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours
2009
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
2011
Radiolabelling DOTA-peptides with 68Ga
2005
Determination of dose components in phantoms irradiated with an epithermal neutron beam for boron neutron capture therapy
1995
Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice
2012
Boron Neutron Capture Therapy
1991
Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
2004
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
2004